Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid generic drug reimbursement caps recommended for all products in HHS IG report.

Executive Summary

MEDICAID GENERIC REIMBURSEMENT CAP COULD SAVE $133 MIL. OVER TWO YEARS, the HHS Inspector General suggested in an Aug. 4 report on "Medicaid Pharmacy: Actual Acquisition Cost of Generic Prescription Drug Products." Based on price data for the top 200 generic products reimbursed by Medicaid, the HHS IG found that states paid an estimated $145 mil. more than the cost of the drugs. Of that total, $132.7 mil. was attributable to drugs that do not have an upper limit for Medicaid reimbursement.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel